- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03306849
Ultrasonographic Evaluation of Anovulatory Disorders in Lean and Overweight Women
Study Overview
Status
Conditions
Detailed Description
This study is being conducted in order to determine if ultrasound features of the ovaries can be used to reliably diagnose different types of anovulatory disorders in women across all body types. The study will also try to establish whether ultrasound features of the ovary can reflect the degree of reproductive and metabolic problems that a woman with irregular or absent periods might be experiencing. In this way, the researchers can help to maximize the information that can be received when using ultrasound to evaluate patients with concerns over irregular menstrual cycles and/or infertility.
The ovaries are the site of egg production and normally release one egg every month. The process of releasing an egg is called ovulation. The act of releasing an egg is the body's way of ensuring a woman's fertility each month during her reproductive years. There are a number of reasons why ovulation may not occur regularly in women. Some of these reasons are believed to relate to male hormone production (i.e. androgens), body composition, nutrition and overall metabolic health. However, the precise ways in which these factors affect ovulation are unknown.
The researchers plan to evaluate how the ovaries look and function in a large group of women. Their goal is to recruit both lean and overweight women to this study and include both women that have regular, predictable menstrual cycles as well as those that have infrequent or absent menstrual cycles. The researchers will include women with irregular cycles due to increased androgen production, or hyperandrogenic anovulation - as well as those that have irregular cycles but normal androgen levels or normoandrogenic anovulation. The researchers will use ultrasound to collect information on how the ovaries look and function, and then relate the features of the ovaries to body composition, reproductive and metabolic hormones as well as nutritional factors. Because features of the ovaries are expected to be different in lean and overweight women, the researchers hope to develop ultrasound criteria that will help healthcare providers to diagnosis specific ovulation problems in women across all body sizes. Together, this research will help to better understand the complex relationship between nutrition, metabolism and reproductive health in women.
To accomplish these objectives, the investigators plan to recruit 50 women with regular menstrual cycles, 50 women with normoandrogenic anovulation, and 50 women with hyperandrogenic anovulation. Their goal is to recruit an equal number of women in each group who are lean (BMI; Normal weight = 18.5 - 24.9 kg/m2) and overweight or obese (BMI; Overweight = 25 - 29.9 kg/m2; Obese >= 30kg/m2). Ultrasound scans of the ovaries will be assessed for the total number, size, and distribution of follicles using both two- and three-dimensional imaging techniques. Participants will have blood samples collected determine serum concentrations of luteinizing hormone (LH), follicle stimulating hormone (FSH), estradiol, progesterone. The following metabolic parameters will be assessed: (1) 75-gram oral glucose tolerance test to characterize glucose and insulin dynamics at 0, 30, 60, 90, and 120 minutes post-glucose ingestion; (2) dual X-ray absorptiometry (DXA) scan to quantify body fat and lean muscle distribution; (3) vitals and anthropometry assessment to measure waist and hip circumference, height, weight, blood pressure, and heart rate, and (4) fasting blood tests to detect serum concentrations of androgens (i.e., total testosterone, androstenedione, free androgen index) and serum markers of metabolic syndrome (i.e., lipids and hemoglobin A1C). Participants will complete a food frequency questionnaire and physical activity questionnaire. A researcher may also provide participants with an accelerometer to wear for a week.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
New York
-
New York, New York, United States, 10065
- Clinical and Translational Science Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Aged 18-45 years
- At least 2y post-menarche
- BMI >18.5kg/m2
- Good visibility of the ovaries on ultrasound
Either:
- Regular menstrual cycles (21-35 days);
- Irregular menstrual cycles (>35 days); or
- Previous diagnosis of PCOS from a primary care provider
Exclusion Criteria:
- Weight >300lbs
- Currently pregnant or breast feeding
- History of ovarian surgery
- Use of medications or supplements known or suspected to interfere with reproductive function and/or glucose and lipid metabolism in the past 3 months
- Evidence of reproductive aging as assessed by the principal criteria of STRAW+10 stages
Study Plan
How is the study designed?
Design Details
- Observational Models: Case-Control
- Time Perspectives: Cross-Sectional
Cohorts and Interventions
Group / Cohort |
---|
Regular menstrual cycles
Women will be assigned to this category if they report a history of regular menstrual cycles (every 21 to 35 days).
Recruitment will be targeted such that equal numbers of lean (BMI <25kg/m2) and overweight or obese (BMI >24.9kg/m2) participate.
|
Normoandrogenic anovulation
Women will be assigned to this category if they do not have clinical or biochemical androgen excess and report a history of irregular menstrual cycles (<21 days or >35 days), including women with a pre-existing diagnosis of PCOS.
Recruitment will be targeted such that equal numbers of lean (BMI <25kg/m2) and overweight or obese (BMI >24.9kg/m2) participate.
|
Hyperandrogenic anovulation
Women will be assigned to this category if they have clinical or biochemical androgen excess and report a history of irregular menstrual cycles (<21 days or >35 days), including women with a pre-existing diagnosis of PCOS.
Recruitment will be targeted such that equal numbers of lean (BMI <25kg/m2) and overweight or obese (BMI >24.9kg/m2) participate.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Follicle number per ovary
Time Frame: 1 day
|
The number and size of all follicles in each ovary will be assessed by ultrasonography
|
1 day
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Insulin sensitivity
Time Frame: 1 day
|
Insulin sensitivity will be determined by administration of an oral glucose tolerance test and compared across groups.
|
1 day
|
Androgen concentrations
Time Frame: 1 day
|
Total testosterone, androstenedione and free androgen index concentrations in serum will be determined and compared across groups.
|
1 day
|
Serum markers of metabolic syndrome
Time Frame: 1 day
|
Lipids, glucose and HbA1C concentrations will be determined and compared across groups.
|
1 day
|
Body mass index
Time Frame: 1 day
|
The ratio of weight to height will be determined and compared across groups.
|
1 day
|
Body fat distribution
Time Frame: 1 day
|
Percentage and distribution of fat and lean mass as assessed using DXA technology will be compared across groups.
|
1 day
|
Follicle number per cross section
Time Frame: 1 day
|
The number all follicles in a single cross sectional plane of each ovary will be assessed by ultrasonography
|
1 day
|
Ovarian volume
Time Frame: 1 day
|
The size of each ovary will be determined by ultrasonography for each participant and compared across groups.
|
1 day
|
Stromal echogenicity on ultrasound
Time Frame: 1 day
|
The brightness of the ovarian stroma in a single cross section will be determined by ultrasonography for each participant and compared across groups.
|
1 day
|
Ovarian area-stromal area ratio
Time Frame: 1 day
|
The ratio of the stromal area to the total ovarian area of the ovary in a single cross section will be determined by ultrasonography for each participant and compared across groups.
|
1 day
|
LH-FSH ratio
Time Frame: 1 day
|
The ratio of circulating LH to FSH concentrations in the serum will be determined for each participant and compared across groups
|
1 day
|
Hirsutism Score
Time Frame: 1 day
|
Degree of hirsutism as judged by the Ferriman-Gallwey scale will be determined and compared across groups
|
1 day
|
Menstrual Cycle Length
Time Frame: 1 day
|
Average menstrual cycle length as determined by self-reported history will be determined and compared across groups
|
1 day
|
Blood Pressure
Time Frame: 1 day
|
Blood pressure will be determined and compared across groups.
[Time Frame: 1 day]
|
1 day
|
Waist-to-hip ratio
Time Frame: 1 day
|
The ratio of waist circumference to hip circumference will be determined and compared across groups
|
1 day
|
Differences in diet composition assessed via food frequency questionnaire
Time Frame: 1 day
|
A food frequency questionnaire will be administered to assess diet composition for the last three months and will be compared across groups
|
1 day
|
Differences in energy expenditure assessed via a waist-worn accelerometer
Time Frame: 1 week
|
Participants will be asked to wear a small accelerometer device to assess physical activity
|
1 week
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Marla E Lujan, PhD, Cornell University
- Principal Investigator: Steven Spandorfer, MD, Weill Medical College of Cornell University
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 1410015577
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Obesity
-
Central Hospital, Nancy, FranceNot yet recruiting
-
University of MinnesotaNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Active, not recruitingAdolescent ObesityUnited States
-
Helsinki University Central HospitalKarolinska Institutet; Folkhälsan Researech CenterEnrolling by invitation
-
Istanbul Medipol University HospitalMedipol UniversityCompletedObesity, Morbid | Obesity, Adolescent | Obesity, Abdominal | Weight, Body | Obesity, VisceralTurkey
-
Queen Fabiola Children's University HospitalNot yet recruitingMorbid Obesity | Adolescent Obesity | Bariatric SurgeryBelgium
-
Azienda Ospedaliero-Universitaria Consorziale Policlinico...Institute of Biomembranes, Bioenergetics and Molecular Biotechnologies; Istituti... and other collaboratorsCompletedMorbid Obesity | Metabolically Healthy ObesityItaly
-
Washington University School of MedicinePatient-Centered Outcomes Research Institute; Pennington Biomedical Research... and other collaboratorsActive, not recruitingOvernutrition | Nutrition Disorders | Overweight | Body Weight | Pediatric Obesity | Body Weight Changes | Childhood Obesity | Weight Gain | Adolescent Obesity | Obesity, Childhood | Overweight and Obesity | Overweight or Obesity | Overweight AdolescentsUnited States
-
The Hospital for Sick ChildrenCompleted
-
Ihuoma EneliCompletedObesity, ChildhoodUnited States
-
Fundació Sant Joan de DéuNot yet recruitingObesity, Childhood | Obesity, AdolescentSpain